Liver cancer as the world ' s top five high incidence of malignant tumors, in the world, about 700,000 new cases of liver cancer patients each year, 1200000 deaths, in China, the incidence of liver cancer is also increasing year by year. As an immunotherapy, PD-1/PD-L1 inhibiting agent have shown certain advantages in the therapy of a variety of malignant tumors, but the quality of clinical treatment needs to be improved. Studies have shown that anti-angiogenic drugs and related treatments can synergistically improve the anti-cancer ability of PD-1/PD-L1 inhibitors. By combing the principle and application status of programmed death-1 and programmed death ligand-1 inhibitors for liver cancer, it is expected to improve the prognosis of patients with advanced lung cancer, and to explore the concurrent immune-related adverse reactions and efficacy evaluation indicators, so as to better apply in clinical practice and achieve satisfactory therapeutic effects.